TABLE 3.

Hospitalizations and outcomes

Characteristic	Value for patients infected with:		P value
	Macrolide-resistant isolates (n = 27)	Macrolide-susceptible isolates (n = 333)
No. (%) of patients with the following complications:
Encephalitis/encephalopathy	0	3 (0.9)	0.99
Hematologic	0	3 (0.9)	0.99
Dermatologic	1 (3.7)	0	0.08
Rheumatologic	0	1 (0.3)	0.99
Other	0	7 (2.1)	0.99
No. (%) of patients with ICU admission	2 (7.4)	44 (13.2)	0.19
Mean ± SD (range) hospitalization duration (days)	5.2 ± 4.5 (0–14)	5.7 ± 11.5 (0–110)	0.38
Mean ± SD (range) duration of fever of >101°F (days)	1.7 ± 2.0 (0–5)	0.89 ± 1.22 (0–7)	0.33
No. (%) of patients hospitalized
Yes	13 (48.2)	201 (60.5)	0.45
No	13 48.2)	121 (36.5
Unknown	1 (3.6)	10 (3.0)
No. (%) of patients with the following outcome of hospitalization:
Survived and discharged	12 (44.4)	205 (61.6)
Died	0	1 (0.3)	0.99
Unknown	0	4 (1.2)
No. (%) of patients administered the following other treatments:
O2 per nasal cannula	3 (11.1)	93 (27.9)	0.07
Extracorporeal membrane oxygenation	0	1 (0.3)	0.99
CPAP/BIPAPa	0	12 (3.6)	0.61
Mechanical ventilation	0	13 (3.9)	0.61
Other	2 (7.4)	14 (4.2)	0.34

^aCPAP/BIPAP, continuous positive airway pressure/bilevel positive airway pressure.